At least two five-star fund managers are looking past this week's market gyrations and offering investors what they think are some promising stock opportunities.
Michael Lippert of Baron Funds focuses on some Internet-related equities, while Michael Cuggino of Permanent Portfolio Funds sees biotech as a buy.
Lippert likes online diamond retailer Blue Nile.
"They're taking massive share from their competition," he told CNBC. "The online business model is just better than the offline model."
He also recommends Equinix.
"They operate data centers that act as on-ramps of the Internet, so everything that's driving Internet growth is driving their business," he said.
Cuggino's biotech names include Amgen.
"On Aranesp, we're hearing some news out of the FDA today," he said.
Aranesp and other anti-anemia drugs had combined sales of more than $6 billion last year.